Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Aug 12, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people who have thoughts of suicide or have recently attempted suicide. The goal is to see if using a mobile app along with brief therapy can help individuals learn skills to manage their negative emotions and reduce emotional distress and suicidal thoughts. Participants will learn three specific skills to cope with their feelings and will receive reminders on their smartphones to practice these skills.
To be eligible for this study, you must be an adult (18 years or older) who has either made a recent suicide attempt or is currently experiencing suicidal thoughts. You should also be able to speak and write in English and have a smartphone with internet access. If you decide to join, you can expect to engage in therapy sessions and use the mobile app as part of your treatment. This trial is currently looking for participants, and it offers a chance to try a new approach to improving mental health in a supportive environment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult status (18+ years),
- • a recent suicide attempt or any report of current suicidal ideation,
- • the ability to speak and write English fluently, ownership of and consistent access to an internet-capable smartphone (e.g., an iPhone or Android phone), and
- Exclusion criteria:
- • - the presence of any factor that impairs an individual\'s ability to provide informed consent and comprehend and effectively participate in the study including: an inability to speak or write English fluently, the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior.
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Piscataway, New Jersey, United States
Patients applied
Trial Officials
EVAN KLEIMAN, Ph.D.
Principal Investigator
Rutgers, The State University of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported